“十四五”期间 国家药品抽检合格率稳定在99.4%以上

Core Viewpoint - During the "14th Five-Year Plan" period, China is comprehensively deepening the reform of drug and medical device regulation to promote high-quality development in the pharmaceutical industry, with a national drug inspection pass rate stabilizing at over 99.4% [1] Group 1 - The National Medical Products Administration (NMPA) supports enterprises in conducting global clinical trials simultaneously, aiming to shorten the global market launch cycle for drugs [1] - The NMPA encourages foreign-invested enterprises to introduce original research drugs, biological products, and high-end medical equipment for domestic production [1] - The scope of export sales certification for drugs and medical devices is being expanded to provide strong support for the internationalization of Chinese pharmaceuticals [1] Group 2 - The establishment of three regional centers in Beijing-Tianjin-Hebei, Central China, and Southwest China is being accelerated [1] - A scientific action plan for drug regulation is being implemented to expedite the development of new regulatory tools, standards, and methods [1]